Home > Gastroenterology > DDW 2024 > DDW 2024 Highlights Podcast

DDW 2024 Highlights Podcast

Presented by
Robert van den Heuvel, Medicom
DDW 2024

In this episode [13.42], Medicom’s correspondent covers 6 presentations from the Digestive Disease Week (DDW 2024), held in Washington DC, USA, from 18-21 May 2024.
The topics discussed are:

  1. GALAXI 2 & 3: Guselkumab proves efficacy in Crohn’s disease
    Guselkumab demonstrated superior short and long-term clinical and endoscopic outcomes compared with ustekinumab and placebo in participants with moderate to severe Crohn’s disease, according to results from the GALAXI 2 & 3 trials at weeks 12 and 48.
  2. Hormone-containing therapies may increase the risk of gut-brain disorders
    A large-scale, retrospective study of 712,741 women found that hormone-containing contraceptives and hormone replacement therapy may be linked to irritable bowel syndrome and functional dyspepsia.
  3. COX-2 inhibitors show promise in reducing the severity of acute pancreatitis
    The efficacy and safety of cyclooxygenase-2 inhibitors were evaluated in a prospective, multicentre trial, which demonstrated a significant reduction in the occurrence and duration of severe acute pancreatitis.
  4. STARS: Apraglutide shows efficacy in patients with SBS-IF
    Apraglutide, a long-acting glucagon-like peptide-2 analogue, significantly reduced parenteral support volume in patients with short bowel syndrome with intestinal failure. Conducted across 73 centres in 18 countries, the trial confirmed the efficacy and safety of apraglutide in this population.
  5. REGENERATE study: Obeticholic acid shows antifibrotic benefit in NASH
    The phase 3 REGENERATE study of the farnesoid X receptor agonist obeticholic acid demonstrated significant antifibrotic benefits in patients with nonalcoholic steatohepatitis.
  6. Promising data for cardiovascular outcomes of bariatric surgery in patients with obesity
    Bariatric surgery was compared with glucagon-like peptide-1 receptor agonists in patients with obesity. Primary endpoints included incident heart failure, composite cardiovascular events, and composite cerebrovascular events. The results favoured the bariatric surgery option.

Enjoy Listening!

Copyright ©2024 Medicom Medical Publishers

Posted on